Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility

Collegium Pharmaceutical overview

Collegium Pharmaceutical (COLL) has drawn attention after recent trading showed a 2.4% daily decline and a 21% drop over the past month, contrasting with a 17.9% total return over the past year.

See our latest analysis for Collegium Pharmaceutical.

The recent 21.2% 1 month share price decline, alongside a weaker 22.2% year to date share price return, contrasts with a stronger 17.9% 1 year total shareholder return. This suggests longer term holders have still fared better than recent buyers.

If recent volatility has you comparing opportunities, this is a good moment to broaden your watchlist and check out 20 top founder-led companies

With Collegium showing mixed recent returns but trading at a level that implies a potential intrinsic discount, investors now face a key question: is today’s price a genuine opening, or is the market already factoring in future growth?

Most Popular Narrative: 34.2% Undervalued

Collegium Pharmaceutical’s most followed narrative pegs fair value at $53.83 per share versus the last close of $35.44, framing a sizeable valuation gap for investors to assess.

The company’s differentiated pain portfolio, notably with products featuring proprietary abuse-deterrent and extended-release technologies (e.g., Xtampza ER’s DETERx platform), is supported by industry and regulatory trends that increasingly favor safer opioid options, which may enhance market share and pricing power and sustain net margins as regulatory emphasis on abuse deterrence grows.

Read the complete narrative.

Want to understand why this story supports a higher fair value? The core assumptions blend slower top line expectations with meaningfully higher margins and a different earnings multiple than today. The tension between these inputs is what drives the 34.2% discount.

Result: Fair Value of $53.83 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the picture could change if patent expiries invite meaningful generic competition, or if higher operating costs are not offset by the expected margin improvements.

Find out about the key risks to this Collegium Pharmaceutical narrative.

Another way to look at value

The first narrative leans heavily on future cash flows and fair value at $53.83. On simple earnings, though, Collegium trades on a P/E of 17.9x, slightly above the US Pharmaceuticals average of 16.6x but well below a peer average of 38.1x and an estimated fair ratio of 23.4x. That split hints at both valuation risk and potential upside if sentiment shifts. Which reference point do you trust most?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages on value and risk so far? Take a closer look at the numbers and sentiment yourself, then weigh up the 3 key rewards and 2 important warning signs.

Ready to find your next idea?

Collegium might be on your radar, but your portfolio deserves more than one story. Use focused stock lists to spot opportunities before they get crowded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com